Forever medical science has believed that genes determined our biological destiny, until now. Latest research by neurogenetics researcher, Dr. Rudolph Tanzi (Rudy), recognized as Time’s 100 Most Influential People in the World, has discovered that genes are dynamic and respond to our thoughts, habits and actions. This discovery is monumental, proving the ability to change your future and the future of your bloodline through simple changes in lifestyle that boost genetic activity and personal transformation. This conversation reveals many of these lifestyle epigenetic modifications that can help and hurt your genes.
01:13:33 | 2015
Dr. Rudolph Tanzi is the Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the McCance Center for Brain Health at Massachusetts General Hospital and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.
Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990. In his research achievements, Dr. Tanzi served on the team that was the first to find a disease gene (Huntington’s disease) using human genetic markers, helping to launch the field of neurogenetics. Dr. Tanzi then went on to co-discovered all three early-onset familial Alzheimer’s disease genes. He has identified several other AD genes as leader of the Alzheimer’s Genome Project supported by the Cure Alzheimer’s Fund. Dr. Tanzi also discovered the Wilson’s disease gene and several other neurological disease genes.
More recently, Dr. Tanzi and his team used Alzheimer’s genes and human stem cells to create “Alzheimer’s-in-a-Dish” - a three-dimensional human stem cell-derived neural culture system that was the first to recapitulate both pathological hallmarks of Alzheimer’s disease: plaques and tangles. This model has made drug screening for Alzheimer’s disease considerably faster and more effective. Using this system, Dr. Tanzi has developed several novel therapies for AD including gamma secretase modulators aimed at plaque pathology.
Most recently, Dr. Tanzi and his team have discovered that beta-amyloid, the main component of senile plaques, may play a role in the innate immune system of the brain operating as an anti-microbial peptide, suggesting a possible role for infection in the etiology and pathogenesis of AD.